Core Viewpoint - Fulgent Genetics reported better-than-expected Q2 2025 results, with significant revenue growth and a raised full-year revenue outlook, despite a wider GAAP loss due to a one-time impairment [1][11]. Financial Performance - Q2 2025 GAAP revenue was $81.8 million, exceeding the analyst consensus estimate of $76.2 million, representing a 15.2% year-over-year increase from $71.0 million in Q2 2024 [2]. - Non-GAAP earnings per share were $0.07, outperforming the anticipated $(0.18) loss, although this reflects a 53.3% decline from $0.15 in Q2 2024 [2]. - Non-GAAP gross margin improved to 44.2%, up from 40.1% in the prior year [2]. - Adjusted EBITDA was a loss of $3.0 million, widening from a loss of $0.7 million in the same period last year [2]. - Total liquidity was $777.5 million, supporting ongoing investments and potential share repurchases [10]. Business Segments - The Laboratory Services segment drove the majority of revenue, with core revenue reaching $81.7 million, up 16% year-over-year, primarily due to reproductive health diagnostics and strong legacy test volumes [5]. - The Therapeutic Development segment is advancing clinical trials for cancer drug candidates, with FID-007 in phase 2 and FID-022 entering phase 1, indicating long-term growth potential [7]. - The biopharma services division expanded its offerings, with revenue from anatomic pathology returning to year-over-year growth after investments in digital systems [8]. Strategic Initiatives - Significant investments in digital pathology and AI are enhancing productivity and improving turnaround times for laboratory workflows [6]. - The company is focusing on product innovation, expanding partnerships, and compliance with healthcare regulations to meet market demands [4]. Future Outlook - Management raised the FY2025 core revenue outlook to $320 million, citing strong order momentum and new client wins [11]. - The company expects a GAAP loss of approximately $(2.10) per share for FY2025, reflecting the one-time impairment, and a smaller non-GAAP loss of $(0.35) per share [11].

Core Insights - Fulgent Genetics experienced a significant stock price increase of over 8% following its second-quarter earnings release, contrasting with a nearly 2% decline in the S&P 500 index [1] Financial Performance - The company reported second-quarter revenue of nearly $82 million, representing a year-over-year increase of more than 15% [2] - Non-GAAP adjusted net income fell sharply by 56% to just over $2 million, equating to $0.07 per share [2] Analyst Expectations - Analysts had anticipated worse results, projecting an adjusted bottom-line loss of $0.18 per share on revenue of only $76 million [4] Strategic Progress - Fulgent attributed its better-than-expected results to diversification efforts, with CEO Ming Hsieh noting progress in growing revenue from laboratory services and advancing clinical trials for therapeutic development [4] Future Guidance - The company raised its revenue and adjusted bottom-line guidance for full-year 2025, now expecting "core" revenue of approximately $320 million and an adjusted net loss of $0.35 per share, surpassing analyst projections of a $0.55 net loss and revenue under $311 million [5]

Fulgent Genetics (FLGT) Q2 2025 Earnings Call August 01, 2025 08:30 AM ET Speaker0Greetings and welcome to the Folder Genetics Q2 twenty twenty five Conference Call and Webcast. At this time, participants are in a listen only mode. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Lauren Sloane, Investor Relations. Please go ahead.Speaker1Thank you, and good morning, and welcome to the Fulgent second quarter twenty twenty five financial results conference call. O ...

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +130.43%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced earnings of $0.04, delivering a surprise of +121.05%.Over the last four qua ...

Investor Presentation 255 126 22 August 1, 2025 Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company" or "Fulgent") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, a ...

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) (626) 350-0537 (Registrant's telephone numbe ...

Exhibit 99.1 Fulgent Reports Second Quarter 2025 Financial Results EL MONTE, CA, August 1, 2025 — Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Results: Note: 1) Core Revenue is revenue calculated in accordance with GAAP minus revenue from COVID-19 testing products and s ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1] Group 1: Investigation Details - The investigation is prompted by claims from investors of Fulgent Genetics, Inc. [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed receiving a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3] - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [3] Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Company Overview - Fulgent Genetics, Inc. is a biotechnology company that specializes in diagnostic and genetic laboratory testing services and develops pharmaceutical treatments for various diseases and medical conditions [3] Allegations and Investigations - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Fulgent, stemming from allegations of providing potentially misleading business information to investors [1] - On February 28, 2025, Fulgent disclosed in its annual report that it received a civil investigative demand from the U.S. Department of Justice related to potential false claims submitted under the federal COVID-19 testing program for uninsured individuals [4] Market Reaction - Following the disclosure of the civil investigative demand, Fulgent's stock price declined by $0.41 per share, or approximately 2.61%, closing at $15.28 per share on March 3, 2025 [5]

Core Viewpoint - Fulgent Genetics, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a civil investigative demand from the U.S. Department of Justice regarding false claims submitted under the Uninsured Program [1][2]. Group 1: Company Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Fulgent on behalf of its stockholders [1]. - The investigation is focused on whether Fulgent has engaged in unlawful business practices or violated federal securities laws [1]. - Following the disclosure of the civil investigative demand, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share [2]. Group 2: Legal Context - The civil investigative demand was received by Fulgent from the U.S. Department of Justice, indicating serious scrutiny regarding the company's claims under the Uninsured Program [2]. - The law firm Bragar Eagel & Squire, P.C. specializes in representing investors in complex litigation, which includes securities and derivative cases [4].